Evidence map›Paper›PMID 33361123›Full record

ArticlemSphere2020

Distinct Immunoglobulin Fc Glycosylation Patterns Are Associated with Disease Nonprogression and Broadly Neutralizing Antibody Responses in Children with HIV Infection.

M Muenchhoff, A W Chung, J Roider, Anne-Sophie Dugast, Simone Richardson, Henrik Kløverpris, Alasdair Leslie, Thumbi Ndung'u, Penny Moore, Galit Alter and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mSphere, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.1field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 6 countries.

M Muenchhoff *Department of Paediatrics, University of Oxford, Oxford, United Kingdom muenchhoff@mvp.lmu.de.ORCID 0000-0001-7016-0470
A W Chung *Department of Immunology and Microbiology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
J Roider *Department of Paediatrics, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-1347-2838
Anne-Sophie Dugast *Rubius Diagnostics, Cambridge, Massachusetts, USA.
Simone RichardsonCentre for HIV and STI's, National Institute for Communicable Diseases, Johannesburg, South Africa.
Henrik KløverprisAfrica Health Research Institute (AHRI), Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
Alasdair LeslieAfrica Health Research Institute (AHRI), Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
Thumbi Ndung'uHIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
Penny MooreCentre for HIV and STI's, National Institute for Communicable Diseases, Johannesburg, South Africa.ORCID 0000-0001-8719-4028
Galit Alter *The Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, Massachusetts, USA.
Philip J R Goulder *Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
University of Oxford · GBRagon Institute of MGH, MIT and Harvard · USUniversity of the Witwatersrand · ZAAfrica Health Research Institute · ZARubius Therapeutics (United States) · USThe University of Melbourne · AUUniversity of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A prophylactic HIV vaccine would ideally induce protective immunity prior to sexual debut. Children develop broadly neutralizing antibody (bnAb) responses faster and at higher frequencies than adults, but little is known about the underlying mechanisms or the potential role of Fc-mediated effector functions in disease progression. We therefore performed systems immunology, with immunoglobulin profiling, on HIV-infected children with progressive and nonprogressive disease. Pediatric nonprogressors (PNPs) showed distinct immunoglobulin profiles with an increased ability to elicit potent Fc-mediated natural killer (NK)-cell effector functions. In contrast to previous reports in adults, both groups of children showed high levels of gp120-specific IgG Fc glycan sialylation compared to bulk IgG. Importantly, higher levels of Fc glycan sialylation were associated with increased bnAb breadth, providing the first evidence that Fc sialylation may drive affinity maturation of HIV-specific antibodies in children, a mechanism that could be exploited for vaccination strategies.

Indexed as

AdolescentAIDS VaccinesBroadly Neutralizing AntibodiesChildFemaleGlycosylationHIV AntibodiesHIV InfectionsHumansImmunoglobulin GMaleReceptors, FcAIDS VaccinesBroadly Neutralizing AntibodiesHIV AntibodiesImmunoglobulin GReceptors, Fcbroadly neutralizing antibodies (bnAbs)Fc effector functionsFc glycosylationHIVnonneutralizing antibodiespediatricvaccine

Identifiers

PMID33361123
PMCPMC7763548
OpenAlexW3117044099

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.